DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Ragni M, Kulkarni R, Pasi J, et al.
B-YOND final results confirm established safety, sustained efficacy, and extended dosing interval for up to 4 years of treatment with rFIXFc in previously treated subjects with severe hemophilia B.
Paper presented at: ASH 2018
Access:
We do not assume any responsibility for the contents of the web pages of other providers.